Author: Oncotarget

Targeting the multifaceted BRAF in cancer: New directions

New Directions in Targeting the Multifaceted BRAF in Cancer

August 12, 2024

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.” BUFFALO, NY- August 12,… read more

Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival

Oncotarget

TCR CDR3s and Renalase-1 Linked to Increased Melanoma Survival

August 8, 2024

“These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.” BUFFALO, NY- August 8, 2024 – A… read more

Oncotarget

Dealing with Runaway Metastatic Disease

August 7, 2024

"Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.” BUFFALO, NY - August 7, 2024 – A new editorial paper was… read more

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death

Oncotarget

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death

August 5, 2024

“INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.” BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled,… read more

Oncotarget

Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167

May 30, 2024

Dr. Benoit Chabot from Université de Sherbrooke discusses a research paper he co-authored that was published by Oncotarget, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167… read more

Oncotarget

Behind the Study: Osteopontin Induces Mitochondrial Biogenesis in Deadherent Cancer Cells

December 14, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, James L. Winkle College of Pharmacy, details a research paper he co-authored that was published by Oncotarget in… read more

Oncotarget

Behind the Study: HER3: A Vital Target in Cancer Treatment

October 12, 2023

Dr. Omkar Desai from the Department of Surgery at Case Western Reserve University and University Hospitals Cleveland Medical Center, describes a research perspective he co-authored with Dr. Rui Wang that… read more

Oncotarget

Why We Ride: Misha Pletnikov

June 23, 2023

My name is Misha Pletnikov, I am chair of the department of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences of the University at Buffalo. I… read more

Oncotarget

Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts

May 25, 2023

Dr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular… read more

Oncotarget

Behind the Study: Role of Biomarkers in Management of Lumps in the Breast

May 10, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, describes a recent research perspective he authored that was published by Oncotarget in Volume 14, entitled, “Crossroads: the… read more